US GAO survey on user fee small business class
This article was originally published in Clinica
95% of device companies that qualified as small businesses under the US' MDUFMA legislation had revenues of less than $30m, and most of the rest have revenues of $30-70m in fiscal 2006. The threshold for qualification - and reduced fees - is $100m, as established in 2002.
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.